- Home
- MAIA vs CMRX Comparison
MAIA vs CMRX Comparison
Compare MAIA & CMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAIA
- CMRX
- Stock Information
- Founded
- MAIA 2018
- CMRX 2000
- Country
- MAIA United States
- CMRX United States
- Employees
- MAIA N/A
- CMRX N/A
- Industry
- MAIA Biotechnology: Pharmaceutical Preparations
- CMRX Biotechnology: Pharmaceutical Preparations
- Sector
- MAIA Health Care
- CMRX Health Care
- Exchange
- MAIA Nasdaq
- CMRX Nasdaq
- Market Cap
- MAIA 62.4M
- CMRX 77.0M
- IPO Year
- MAIA 2022
- CMRX 2013
- Fundamental
- Price
- MAIA $2.82
- CMRX $0.93
- Analyst Decision
- MAIA
- CMRX Strong Buy
- Analyst Count
- MAIA 0
- CMRX 1
- Target Price
- MAIA N/A
- CMRX $11.00
- AVG Volume (30 Days)
- MAIA 60.0K
- CMRX 119.4K
- Earning Date
- MAIA 11-05-2024
- CMRX 11-08-2024
- Dividend Yield
- MAIA N/A
- CMRX N/A
- EPS Growth
- MAIA N/A
- CMRX N/A
- EPS
- MAIA N/A
- CMRX N/A
- Revenue
- MAIA N/A
- CMRX $144,000.00
- Revenue This Year
- MAIA N/A
- CMRX $3,040.12
- Revenue Next Year
- MAIA N/A
- CMRX N/A
- P/E Ratio
- MAIA N/A
- CMRX N/A
- Revenue Growth
- MAIA N/A
- CMRX N/A
- 52 Week Low
- MAIA $0.82
- CMRX $0.75
- 52 Week High
- MAIA $5.99
- CMRX $1.30
- Technical
- Relative Strength Index (RSI)
- MAIA 50.98
- CMRX 60.78
- Support Level
- MAIA $2.36
- CMRX $0.80
- Resistance Level
- MAIA $2.72
- CMRX $0.98
- Average True Range (ATR)
- MAIA 0.22
- CMRX 0.05
- MACD
- MAIA 0.02
- CMRX 0.01
- Stochastic Oscillator
- MAIA 72.28
- CMRX 83.33
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company. The company develops targeted immunotherapies for cancer. The company is an immune-oncology company, focused on the development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's program is THIO, a potential cancer telomere-targeting agent in clinical development for the treatment of telomerase-positive cancer cells.
About CMRX Chimerix Inc.
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.